A randomised, placebo-controlled trial investigating the role of fampiridina in cerebral circuits involved in cognitive and motor function of patients with multiple sclerosis.

Trial Profile

A randomised, placebo-controlled trial investigating the role of fampiridina in cerebral circuits involved in cognitive and motor function of patients with multiple sclerosis.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 28 Apr 2017

At a glance

  • Drugs Fampridine (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Apr 2017 Primary endpoint (Improvement in the SDMT score) has been met, according to results presented at the 69th Annual Meeting of the American Academy of Neurology.
    • 28 Apr 2017 Status changed from recruiting to active, no longer recruiting, according to results presented at the 69th Annual Meeting of the American Academy of Neurology.
    • 28 Apr 2017 Results assessing the efficacy of Dalfampiridine, presented at the 69th Annual Meeting of the American Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top